论文部分内容阅读
本报讯(记者柯蓝)如今,早期关注个人和社会功能的改善已成为当今精神分裂症治疗领域中众多专家的共识。2月13日,西安杨森制药有限公司在北京宣布,被PSP量表证明能够有效控制精神分裂症状,改善患者社会功能的新型抗精神分裂症治疗药物—芮达(Invega),获国家食品药品监督管理局批准正式在中国上市。
WASHINGTON - Early attention to the improvement of personal and social functioning has become the consensus of many experts in the field of schizophrenia today. On February 13, Xi’an Janssen Pharmaceutical Co., Ltd. announced in Beijing that it has been proven by the PSP scale that it can effectively control schizophrenia and improve the social functions of patients with a new anti-schizophrenic drug - Invega, which won the National Food and Drug Administration Authority approved the official listing in China.